BRAIN BIOTECH AG (BNN.DE) Fundamental Analysis & Valuation

FRA:BNN • DE0005203947

Current stock price

2.48 EUR
+0.08 (+3.33%)
Last:

This BNN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BNN.DE Profitability Analysis

1.1 Basic Checks

  • BNN had negative earnings in the past year.
  • In the past year BNN has reported a negative cash flow from operations.
  • BNN had negative earnings in each of the past 5 years.
  • In the past 5 years BNN always reported negative operating cash flow.
BNN.DE Yearly Net Income VS EBIT VS OCF VS FCFBNN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -15.88%, BNN is doing worse than 82.61% of the companies in the same industry.
Industry RankSector Rank
ROA -15.88%
ROE N/A
ROIC N/A
ROA(3y)-13.97%
ROA(5y)-11.35%
ROE(3y)-254.67%
ROE(5y)-159.82%
ROIC(3y)N/A
ROIC(5y)N/A
BNN.DE Yearly ROA, ROE, ROICBNN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • The Gross Margin of BNN (59.16%) is better than 88.41% of its industry peers.
  • BNN's Gross Margin has been stable in the last couple of years.
  • BNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.36%
BNN.DE Yearly Profit, Operating, Gross MarginsBNN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BNN.DE Health Analysis

2.1 Basic Checks

  • BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BNN has about the same amount of shares outstanding.
  • Compared to 5 years ago, BNN has more shares outstanding
  • BNN has a worse debt/assets ratio than last year.
BNN.DE Yearly Shares OutstandingBNN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
BNN.DE Yearly Total Debt VS Total AssetsBNN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.79%
BNN.DE Yearly LT Debt VS Equity VS FCFBNN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M 40M

2.3 Liquidity

  • A Current Ratio of 1.48 indicates that BNN should not have too much problems paying its short term obligations.
  • BNN has a Current ratio (1.48) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.48 indicates that BNN should not have too much problems paying its short term obligations.
  • BNN has a better Quick ratio (1.48) than 72.46% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.48
BNN.DE Yearly Current Assets VS Current LiabilitesBNN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BNN.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.13% over the past year.
  • BNN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.20%.
  • BNN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.15% yearly.
EPS 1Y (TTM)15.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
Revenue 1Y (TTM)-12.2%
Revenue growth 3Y-0.05%
Revenue growth 5Y5.15%
Sales Q2Q%-9.11%

3.2 Future

  • BNN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.84% yearly.
  • Based on estimates for the next years, BNN will show a small growth in Revenue. The Revenue will grow by 7.06% on average per year.
EPS Next Y-39.18%
EPS Next 2Y49.11%
EPS Next 3Y-5.84%
EPS Next 5YN/A
Revenue Next Year-2.53%
Revenue Next 2Y9.33%
Revenue Next 3Y1.58%
Revenue Next 5Y7.06%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BNN.DE Yearly Revenue VS EstimatesBNN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20M 40M 60M 80M 100M
BNN.DE Yearly EPS VS EstimatesBNN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. BNN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 56.67, BNN can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, BNN is valued a bit more expensive than the industry average as 69.57% of the companies are valued more cheaply.
  • When comparing the Price/Forward Earnings ratio of BNN to the average of the S&P500 Index (22.67), we can say BNN is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 56.67
BNN.DE Price Earnings VS Forward Price EarningsBNN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNN.DE Per share dataBNN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as BNN's earnings are expected to decrease with -5.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.11%
EPS Next 3Y-5.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNN.DE Dividend Analysis

5.1 Amount

  • BNN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNN.DE Fundamentals: All Metrics, Ratios and Statistics

BRAIN BIOTECH AG

FRA:BNN (3/24/2026, 7:00:00 PM)

2.48

+0.08 (+3.33%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-25
Earnings (Next)05-28
Inst Owners8.22%
Inst Owner ChangeN/A
Ins Owners52.2%
Ins Owner ChangeN/A
Market Cap54.19M
Revenue(TTM)49.01M
Net Income(TTM)-10.62M
Analysts86.67
Price Target5.34 (115.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.76%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-44.64%
EPS NY rev (3m)-227.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.42%
Revenue NY rev (3m)-13.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 56.67
P/S 1.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)0.04
Fwd EY1.76%
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS2.24
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.16%
FCFM N/A
ROA(3y)-13.97%
ROA(5y)-11.35%
ROE(3y)-254.67%
ROE(5y)-159.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.36%
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.48
Altman-Z N/A
F-Score4
WACC6.79%
ROIC/WACCN/A
Cap/Depr(3y)41.29%
Cap/Depr(5y)59.09%
Cap/Sales(3y)3.67%
Cap/Sales(5y)5.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
EPS Next Y-39.18%
EPS Next 2Y49.11%
EPS Next 3Y-5.84%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.2%
Revenue growth 3Y-0.05%
Revenue growth 5Y5.15%
Sales Q2Q%-9.11%
Revenue Next Year-2.53%
Revenue Next 2Y9.33%
Revenue Next 3Y1.58%
Revenue Next 5Y7.06%
EBIT growth 1Y37.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year487.62%
EBIT Next 3Y143.85%
EBIT Next 5YN/A
FCF growth 1Y-28.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.03%
OCF growth 3YN/A
OCF growth 5YN/A

BRAIN BIOTECH AG / BNN.DE Fundamental Analysis FAQ

What is the fundamental rating for BNN stock?

ChartMill assigns a fundamental rating of 2 / 10 to BNN.DE.


What is the valuation status for BNN stock?

ChartMill assigns a valuation rating of 0 / 10 to BRAIN BIOTECH AG (BNN.DE). This can be considered as Overvalued.


How profitable is BRAIN BIOTECH AG (BNN.DE) stock?

BRAIN BIOTECH AG (BNN.DE) has a profitability rating of 1 / 10.


How financially healthy is BRAIN BIOTECH AG?

The financial health rating of BRAIN BIOTECH AG (BNN.DE) is 2 / 10.